Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,511 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07424287RecruitingPhase 3
New drug plus BCG vs chemo for BCG-resistant bladder cancer
This trial tests a new combination treatment (SHR-1501 plus BCG) compared to standard chemotherapy for people with bladder cancer that hasn't responded to BCG. The goal is to see if this combination works better at controlling the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07422935Recruiting
Plant-protein tube feed study
This study tests whether a tube feed that gets most of its protein from plants is as good as a standard tube feed for people who need one at home. It looks at how well your body handles and uses the nutrients.
Trowbridge, WiltshireAges 16 years+ - NCT07417514Recruiting
Tolerance test of an oral nutrition supplement for kidney patients
This study tests how well kidney patients tolerate a new oral nutrition supplement taken by mouth or through a feeding tube. It aims to see if it is acceptable for daily use over 28 days.
LondonAges 18 years+ - NCT07421245Enrolling by invitation
Testing a new stemless shoulder implant for osteoarthritis
This study tests a new stemless shoulder replacement system for people with shoulder arthritis. The implant uses a metal anchor without a stem and a plastic socket that may be cemented or press-fit.
Florham Park, New JerseyAges 20 years+ - NCT07420985RecruitingPhase 2
Ingavirin forte for flu and other viral infections
This trial tests different doses of Ingavirin Forte capsules for treating influenza and other respiratory viruses. It may help people with fever, cough, sore throat, and body aches who have been sick less than 48 hours.
IvanovoAges 18–65 - NCT07421297RecruitingPhase 3
Study of SYH2053 for high cholesterol in Chinese adults
This trial tests a new medication called SYH2053 for people with high cholesterol or mixed high cholesterol and triglycerides. If you have high LDL cholesterol and are not taking strong cholesterol medicines, you may be able to join. The study will see if this drug is safe and works well.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07423299RecruitingPhase 1
First human safety study of MT-251 in healthy volunteers
This is the first human study of a new medication called MT-251. It is a safety study, so healthy volunteers are given either a single dose or multiple doses of the drug to see how the body handles it and if there are any side effects.
San Diego, CaliforniaAges 19–55 - NCT07419841RecruitingPhase 1
A study of CTX-10726 for certain advanced cancers
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Phoenix, ArizonaAges 18 years+ - NCT07417189RecruitingPhase 1/Phase 2
Study of ABSK141 for advanced solid tumors with KRAS G12D mutation
This study tests a new drug called ABSK141 for people with advanced solid tumors that have a specific mutation called KRAS G12D. It aims to see if the drug can shrink or control the cancer, and it has different phases for different groups of patients.
ShanghaiAges 18 years+ - NCT07423533RecruitingPhase 2
GenSci120 injection for moderate to severe rheumatoid arthritis
This trial tests a new injection called GenSci120 for people with moderate to severe rheumatoid arthritis who haven't improved enough after trying at least one standard arthritis medication. The goal is to see if this treatment can help reduce joint pain and swelling.
Beijing, Beijing MunicipalityAges 18–70 - NCT07421700RecruitingPhase 1/Phase 2
Study of PF-08634404 alone or with enfortumab vedotin for bladder cancer
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
Fayetteville, ArkansasAges 18 years+ - NCT07422610RecruitingPhase 1
Study of Pelabresib for advanced cancer with liver issues
This trial tests how the drug pelabresib works in people with advanced cancer who also have mild to severe liver problems. It aims to understand safety and how the drug moves through the body.
BordeauxAges 18–75 - NCT07416994RecruitingPhase 3
Study of YL202 vs. docetaxel for advanced EGFR-mutant lung cancer
This trial tests a new drug, YL202, against a standard chemotherapy (docetaxel) for people with a specific type of advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if YL202 works better for those whose cancer has progressed after prior treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07422857RecruitingPhase 3
A PET scan for detecting signs of Alzheimer's
This trial uses a new type of PET scan to look for specific proteins in the brain that are linked to Alzheimer's disease. It will help doctors see how these proteins relate to cognitive decline and compare scans from people with normal thinking to those with memory problems.
Wuhan, HubeiAges 50 years+ - NCT07416552RecruitingPhase 1
Study of CEA-PRIT 2.0 for advanced colorectal cancer
This trial tests an experimental drug called CEA-PRIT 2.0 in people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
Chicago, IllinoisAges 18 years+ - NCT07416604RecruitingPhase 3
Study of NXT007 vs emicizumab for hemophilia A
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
Orange, CaliforniaAges 12 years+ - NCT07416695RecruitingPhase 1
Study of HLX3901 for advanced lung or neuroendocrine cancer
This trial tests a new drug, HLX3901, for people with advanced small cell lung cancer or neuroendocrine cancer that has worsened after previous treatments. The goal is to see if it's safe and how the body handles it.
BeijingAges 18–75 - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Plantation, FloridaAges 18 years+ - NCT07424677RecruitingPhase 3
Saroglitazar for PBC with incomplete UDCA response
This trial tests a new oral medication, saroglitazar magnesium, for people with Primary Biliary Cholangitis (PBC) who have not improved enough on standard therapy (UDCA) or cannot tolerate it. The goal is to see if it can help control liver enzymes and improve outcomes.
Lakewood Rch, FloridaAges 18–80 - NCT07425639Recruiting
Switching From Omalizumab to OMLYCLO in Asthma or Hives
This study follows patients with severe asthma or chronic hives who are already on omalizumab (Xolair) and are switching to a very similar, lower-cost biosimilar called OMLYCLO. It aims to see if the switch works well in real-world practice.
MontpellierAges 18 years+ - NCT07424261Recruiting
Study of anifrolumab for lupus in routine care
This study follows people with lupus who are starting a new medication called anifrolumab (given as a shot under the skin) as part of their regular medical care. It aims to see how well the medicine works in everyday life.
AltenburgAges 18–130 - NCT07420283RecruitingPhase 2
Study of Brenipatide for opioid use disorder
This trial tests a new medicine called Brenipatide for people with opioid use disorder who are already taking buprenorphine but still occasionally use non-prescribed opioids. It aims to see if the study drug can help reduce opioid use.
Phoenix, ArizonaAges 18–75 - NCT06642792RecruitingPhase 1/Phase 2
Study of AK129 with or without AK117 for Hodgkin lymphoma after PD-1 treatment
This trial tests a new drug, AK129, alone or with another drug called AK117, for people with classic Hodgkin lymphoma that has not responded to or stopped responding to PD-1/L1 inhibitor therapy. The goal is to see if these combinations can help control the cancer.
BeijingAges 18 years+ - NCT04423185RecruitingPhase 2
Precision medicine trial for rare advanced solid tumors
This study tests targeted drugs or immunotherapy based on the genetic features of your tumor. It may help people with rare, advanced cancers whose disease has progressed after standard treatment options.
BeijingAges 18 years+
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,511 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.